Evaluating the Efficacy of Pharmacological Therapy for Prader-Willi Syndrome: A Systematic Review and Meta-analysis

키워드

참고문헌 (68)

1. Luo Y, "Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials", Endocrine, 71(2), pp.321~330 (2021)
2. Shawn E McCandless, "SUN-604 U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims", Journal of the Endocrine Society, 4(1) (2020), The Endocrine Society[DOI]
3. Butler MG, "Behavioral differences among subjects with Prader-Willi syndrome and type 1 or type 2 deletion and maternal disomy", Pediatrics, 113(3 Pt 1), pp.565~573 (2004)
4. Yang L, "Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta analysis", PLoS One, 8(8), pp.e72640~ (2013)
5. Butler MG, "Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update", Curr Pediatr Rev, 15(4), pp.207~244 (2019)
6. Clements AC, "Outcomes of adenotonsillectomy for obstructive sleep apnea in Prader-Willi syndrome : systematic review and meta-analysis", Laryngoscope, (4), pp.898~906 (2021)
7. Kim SJ, "Obesity and metabolic syndrome in adults with Prader-Willi syndrome", J Mucopolysacch Rare Dis, 1(2), pp.44~48 (2015)
8. Tan Q, "Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome : a narrative review", Obes Rev, 21(5), pp.e12992~ (2020)
9. Schmidt H, "Successful early dietary intervention avoids obesity in patients with Prader-Willi syndrome : a ten-year follow-up", J Pediatr Endocrinol Metab, 21(7), pp.651~655 (2008)
10. Felix G, "The modified atkins diet in children with Prader-Willi syndrome", Orphanet J Rare Dis, 15(1), pp.135~ (2020)
11. Miller JL, "Dietary management for adolescents with Prader-Willi syndrome", Adolesc Health Med Ther, 11, pp.113~118 (2020)
12. Passone CGB, "Growth hormone treatment in Prader-Willi syndrome patients : systematic review and metaanalysis", BMJ Paediatr Open, 4(1), pp.e000630~ (2020)
13. Ng NBH, "The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: a systematic review", Clin Endocrinol(Oxf), 96(2), pp.144~154 (2022)
14. Rosenberg AGW, "Growth hormone treatment for adults with Prader-Willi syndrome : a metaanalysis", J Clin Endocrinol Metab, 106(10), pp.3068~3091 (2021)
15. Sanchez-Ortiga R, "Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis", Clin Endocrinol(Oxf), 77(1), pp.86~93 (2012)
16. "Chapter 13: Assessing risk of bias due to missing Results in a Synthesis"[URL]
17. Balshem H, "GRADE guidelines: 3. Rating the quality of evidence", J Clin Epidemiol, 64(4), pp.401~406 (2011)
18. Carrel AL, "Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study", J Pediatr, 134(2), pp.215~221 (1999)
19. Damen L, "Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3months of oxytocin", Clin Endocrinol(Oxf), 94(5), pp.774~785 (2021)
20. Consoli A, "Effect of topiramate on eating behaviours in Prader-Willi syndrome : TOPRADER double-blind randomised placebo-controlled study", Transl Psychiatry, 9(1), pp.274~ (2019)
21. McCandless SE, "Effects of MetAP2inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial", Diabetes Obes Metab, 19(12), pp.1751~1761 (2017)
22. Allas S, "Azp-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: a randomized placebo-controlled trial", PLoS One, 13(1), pp.e0190849~ (2018)
23. Sze L, "Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome", J Clin Endocrinol Metab, 96(8), pp.1314~1319 (2011)
24. Motaghedi R, "Psychiatric adverse effects of rimonobant in adults with prader willi syndrome", Eur J Med Genet, 54(1), pp.14~18 (2011)
25. De Waele K, "Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome", Eur J Endocrinol, 159(4), pp.381~388 (2008)
26. Selikowitz M, "Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial", Arch Dis Child, 65(1), pp.112~114 (1990)
27. Einfeld SL, "A double-blind randomized controlled trial of oxytocin nasal spray in prader willi syndrome", Am J Med Genet A (2014)
28. Kuppens RJ, "Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial", Clin Endocrinol(Oxf), 85(6), pp.979~987 (2016)
29. Hoybye C, "Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with gh treatment", Eur J Endocrinol, 151(4), pp.457~461 (2004)
30. Myers SE, "Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome", J Pediatr, 137(1), pp.42~49 (2000)
31. Höybye C, "The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome", Growth Horm IGF Res, 13(5), pp.269~274 (2003)
32. Haqq AM, "Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome", J Clin Endocrinol Metab, 88(5), pp.2206~2212 (2003)
33. Festen DA, "Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome", Clin Endocrinol(Oxf), 69(3), pp.443~451 (2008)
34. Hauffa BP, "One-year results of growth hormone treatment of short stature in Prader-Willi syndrome", Acta Paediatr Suppl, 423, pp.63~65 (1997)
35. Bakker NE, "Dietary energy intake, body composition and resting energy expenditure in prepubertal children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial", Horm Res Paediatr, 83(5), pp.321~331 (2015)
36. Lindgren AC, "Growth hormone treatment of children with Prader-Willi syndrome : effects on glucose and insulin homeostasis", Horm Res, 51(4), pp.157~161 (1999)
37. Lindgren AC, "Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably", Acta Paediatr, 87(1), pp.28~31 (1998)
38. Carrel AL, "Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome", J Pediatr, 145(6), pp.744~749 (2004)
39. Höybye C, "Growth hormone treatment improves body composition in adults with Prader-Willi syndrome", Clin Endocrinol(Oxf), 58(5), pp.653~661 (2003)
40. Kuppens RJ, "Beneficial effects of GH in young adults with Prader-Willi syndrome : a 2-year crossover trial", J Clin Endocrinol Metab, 101(11), pp.4110~4116 (2016)
41. Festen DA, "Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy", J Clin Endocrinol Metab, 92(4), pp.1549~1554 (2007)
42. Sode-Carlsen R, "One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study", J Clin Endocrinol Metab, 95(11), pp.4943~4950 (2010)
43. de Lind van Wijngaarden RF, "Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment", J Clin Endocrinol Metab, 95(4), pp.1758~1766 (2010)
44. Burman P, "Endocrine dysfunction in Prader-Willi syndrome : a review with special reference to GH", Endocr Rev, 22(6), pp.787~799 (2001)
45. Cadilhac DA, "The economic benefits of reducing physical inactivity : an Australian example", Int J Behav Nutr Phys Act, 8, pp.99~ (2011)
46. Scheimann AO, "Management of Prader-Willi Syndrome", pp.153~200 (2006), Springer
47. Butler MG, "Causes of death in Prader-Willi syndrome : Prader-Willi syndrome association(USA)40-year mortality survey", Genet Med, 19(6), pp.635~642 (2017)
48. Carrek AL, "Management of Prader-Willi Syndrome", pp.201~241 (2006), Springer
49. Butler MG, "Comparison of leptin protein levels in Prader-Willi syndrome and control individuals", Am J Med Genet, 75(1), pp.7~12 (1998)
50. "Body mass index :considerations for practitioners"[URL]
51. Poskitt EM, "Defining childhood obesity : the relative body mass index(BMI)", Acta Paediatr, 84(8), pp.961~963 (1995)
52. Nuttall FQ, "Body mass index: obesity, bmi, and health: a critical review", Nutr Today, 50(3), pp.117~128 (2015)
53. Aycan Z, "Prader-Willi syndrome and growth hormone deficiency", J Clin Res Pediatr Endocrinol, 6(2), pp.62~67 (2014)
54. Paterson WF, "Growth hormone therapy in the Prader-Willi syndrome", Arch Dis Child, 88(4), pp.283~285 (2003)
55. Bakker NE, "Eight years of growth hormone treatment in children with Prader-Willi syndrome : maintaining the positive effects", J Clin Endocrinol Metab, 98(10), pp.4013~4022 (2013)
56. Eiholzer U, "Low insulin, igf-1 and igfbp-3 levels in children with Prader-Labhart-Willi syndrome", Eur J Pediatr, 157(11), pp.890~893 (1998)
57. Muscogiuri G, "Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches", J Endocrinol Invest, 44(10), pp.2057~2070 (2021)
58. Nagai T, "Prader-Willi syndrome, diabetes mellitus and hypogonadism", Biomed Pharmacother, 53(10), pp.452~454 (1999)
59. Qian Y, "Do patients with Prader-Willi syndrome have favorable glucose metabolism?", Orphanet J Rare Dis, 17(1), pp.187~ (2022)
60. Woldaregay AZ, "Toward detecting infection incidence in people with type 1 diabetes using self-recorded data(part 1) : a novel framework for a personalized digital infectious disease detection system", J Med Internet Res, 22(8), pp.e18911~ (2020)
61. Elena G, "Prader-Willi syndrome : clinical aspects", J Obes, 2012, pp.473941~ (2012)
62. 진동규, "Systematic review of the clinical and genetic aspects of Prader-Willi syndrome", Clinical and Experimental Pediatrics, 54(2), pp.55~63 (2011), 대한소아청소년과학회
63. McCormack SE, "Metabolic effects of oxytocin", Endocr Rev, 41(2), pp.121~145 (2020)
64. Møller N, "Metabolic effects of growth hormone in humans", Metabolism, 44(10 Suppl 4), pp.33~36 (1995)
65. Crinò A, "Update on diabetes mellitus and glucose metabolism alterations in Prader-Willi syndrome", Curr Diab Rep, 20(2), pp.7~ (2020)
66. Goodarzi MO, "Fasting insulin reflects heterogeneous physiological processes : role of insulin clearance", Am J Physiol Endocrinol Metab, 301(2), pp.402~408 (2011)
67. Achari AE, "Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction", Int J Mol Sci, 18(6), pp.1321~ (2017)
68. Ouchi N, "Adiponectin as an anti-inflammatory factor", Clin Chim Acta, 380(1-2), pp.24~30 (2007)

관련 논문AI추천